ABL503 (TJ-L14B), PD-L1X4-1BB BISPECIFIC ANTIBODY INDUCES SUPERIOR ANTI-TUMOR ACTIVITY BY PD-L1-DEPENDENT 4-1BB ACTIVATION WITH THE INCREASE OF 4-1BB+CD8+T CELLS IN TUMOR MICROENVIRONMENT

被引：0
|
作者：
Jung, Uijung [1 ]
Jeon, Jaehyoung [1 ]
Lee, Shinai [1 ]
Jin, Hyung-Seung [2 ]
Kim, Youngkwang [1 ]
Sung, Eunsil [1 ]
Kim, Hyunjoo [1 ]
Lim, Yangmi [1 ]
Won, Jonghwa [1 ]
Wang, Zhengyi [3 ]
Jiang, Wenqing [3 ]
Jung, Jaeho [1 ]
You, Gihoon [1 ]
机构：
[1] ABL Bio Inc, Seongnam, South Korea
[2] Asan Med Ctr, Seoul, South Korea
[3] I Mab Biopharma, Shanghai, Peoples R China
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2021年 / 9卷
关键词：
D O I：
10.1136/jitc-2021-SITC2021.892
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
892
引用
收藏
页码：A935 / A935
页数：1
相关论文
共 50 条
  • [1] Striking the Balance with a PD-L1x4-1BB Bispecific Antibody
    Ha, Jonghoon
    Grippin, Adam J.
    Kim, Betty Y. S.
    Jiang, Wen
    CANCER RESEARCH, 2024, 84 (10) : 1546 - 1547
  • [2] ATG-101 Is a Tetravalent PD-L1x4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1-Directed 4-1BB Activation
    Hui, Yuwen
    Wang, Huajing
    Li, Tengteng
    Ren, Yijing
    Zhang, Yun-kai
    Chen, Peng
    Sun, Ao
    Bian, Gang
    Li, Bohua
    Flowers, David
    Presler, Marc
    Subramanian, Kalyanasundaram
    Xue, Jia
    Wang, Jingjing
    Lynch, Kevin
    Mei, Jay
    He, Xiaowen
    Shan, Bo
    Hou, Bing
    CANCER RESEARCH, 2024, 84 (10) : 1680 - 1698
  • [3] An Fc-inert PD-L1x4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation
    Muik, Alexander
    Altintas, Isil
    Gieseke, Friederike
    Schoedel, Kristina B.
    Burm, Saskia M.
    Toker, Aras
    Salcedo, Theodora W.
    Verzijl, Dennis
    Eisel, David
    Grunwitz, Christian
    Kranz, Lena M.
    Vormehr, Mathias
    Satijn, David P. E.
    Diken, Mustafa
    Kreiter, Sebastian
    Sasser, Kate
    Ahmadi, Tahamtan
    Tuereci, Oezlem
    Breij, Esther C. W.
    Jure-Kunkel, Maria
    Sahin, Ugur
    ONCOIMMUNOLOGY, 2022, 11 (01):
  • [4] ATG-101, A NOVEL PD-L1/4-1BB BISPECIFIC ANTIBODY, AUGMENTS ANTI-TUMOR IMMUNITY THROUGH IMMUNE CHECKPOINT INHIBITION AND PDL1-DIRECTED 4-1BB ACTIVATION
    Hui Yuwen
    Li, Tengteng
    Ren, Yijing
    Hoenemann, Dirk
    Mei, Jay
    Shan, Bo
    Hou, Bing
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A936 - A937
  • [5] KEY PHARMACOKINETIC AND PHARMACODYNAMIC PARAMETERS THAT CORRELATE WITH THE ANTI-TUMOR ACTIVITY OF A BISPECIFIC PD-L1 CONDITIONAL 4-1BB AGONIST
    Kinkead, Heather
    Macedo, Chelsie
    Sanabria, Angelica
    Cyprus, Garrett
    Pandit, Rajay
    Kalabus, James
    Becklund, Bryan
    Sulzmaier, Florian
    Timmer, John
    Deveraux, Quinn
    Eckelman, Brendan
    Heidt, Analeah
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A12 - A12
  • [6] Discovery of a novel Claudin 6 X 4-1BB bispecific antibody with potent anti-tumor activity through conditional 4-1BB activation.
    Li, Jian
    Jiang, Wenqing
    Liu, Yan
    Wang, Zhengyi
    Chen, Xi
    Guo, Taylor B.
    CANCER RESEARCH, 2022, 82 (12)
  • [7] GEN1046 (DuoBody®-PD-L1x4-1BB) in combination with PD-1 blockade potentiates anti-tumor immunity
    Capello, Michela
    Sette, Angelica
    Plantinga, Theo
    Spires, Vanessa
    Nuermberger, Kristina
    Blum, Jordan
    Muik, Alexander
    Sa, Carol Costa
    Jabado, Omar
    Burm, Saskia
    Toker, Aras
    Fellermeier-Kopf, Sina
    Ahmadi, Tahi
    Higgs, Brandon
    Couto, Suzana
    Tureci, Ozlem
    Fereshteh, Mark
    Sahin, Ugur
    Jure-Kunkel, Maria
    Pencheva, Nora
    CANCER RESEARCH, 2023, 83 (07)
  • [8] The bispecific antibody KA-3004, targeting PD-L1 and 4-1BB, is designed to enhance anti- tumor activity
    Liang, Jiabei
    Guo, Zhengcheng
    Peng, Hao
    Hao, Feng
    Liu, Tongtong
    Ning, Jinying
    Wu, Guojin
    CANCER RESEARCH, 2024, 84 (06)
  • [9] BATF3 DENDRITIC CELLS AND 4-1BB/4-1BB LIGAND AXIS ARE REQUIRED AT THE EFFECTOR PHASE WITHIN THE TUMOR MICROENVIRONMENT FOR ANTI-PD-L1 EFFICACY
    Ziblat, Andrea
    Horton, Brendan
    Higgs, Emily
    Hatogai, Ken
    Gajewski, Thomas
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A354 - A354
  • [10] DUOBODY®-PD-L1x4-1BB (GEN1046) INDUCES SUPERIOR IMMUNE-CELL ACTIVATION, CYTOKINE PRODUCTION AND CYTOTOXICITY BY COMBINING PD-L1 BLOCKADE WITH CONDITIONAL 4-1BB CO-STIMULATION
    Muik, Alexander
    Altintas, Isil
    Kosoff, Rachelle
    Gieseke, Friederike
    Schoedel, Kristina
    Salcedo, Theodora
    Burm, Saskia
    Toker, Aras
    Kranz, Lena
    Vormehr, Mathias
    Eisel, David
    Fereshteh, Mark
    Tuereci, Oezlem
    Breij, Esther
    Ahmadi, Tahamtan
    Sahin, Ugur
    Jure-Kunkel, Maria
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A338 - A339
12345